Are you interested in helping to inform decisions about research and funding for new Primary Immunodeficiency treatments? Make your voice heard by filling out ImmUnity Canada’s Patient and Caregiver Survey! Access the survey here: https://www.surveymonkey.com/r/Z62HDHC.
The information you provide in the survey will help to ensure that perspectives of the Primary Immunodeficiency (PI) community are considered by decision-makers at the Canadian Agency for Drugs and Technology in Health (CADTH) for a treatment called Leniolisib. Leniolisib is used to treat Activated Phosphoinositide 3-Kinase Delta (PI3K) Syndrome (APDS), a type of PI.
The survey will take approximately 15-30 minutes to complete. Please submit the survey by the 27th of November 2023. NOTE: You do not need to have APDS or experience with Leniolisib to respond to the survey.